272 related articles for article (PubMed ID: 22231637)
1. Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis.
Zhang S; Chen J; Jiang H; Ma H; Yang B
Eur J Clin Pharmacol; 2012 May; 68(5):561-9. PubMed ID: 22231637
[TBL] [Abstract][Full Text] [Related]
2. [Anti-EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: a Meta-analysis].
Song Q; Li X; Li B; Di B; Xiao S
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 May; 29(9):815-21. PubMed ID: 26281058
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of the effects of anti-epidermal growth factor receptor on recurrent/metastatic head and neck squamous cell carcinoma.
Xin Y; Yan Q; Yang C; Jiang F; Guo W; Huang Q; Jiang G; Zhang L
Medicine (Baltimore); 2018 Dec; 97(51):e13717. PubMed ID: 30572506
[TBL] [Abstract][Full Text] [Related]
4. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
Song Q; Li X; Li B
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of anti-EGFR agents administered concurrently with standard therapies for patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis of randomized controlled trials.
Tian Y; Lin J; Tian Y; Zhang G; Zeng X; Zheng R; Zhang W; Yuan Y
Int J Cancer; 2018 Jun; 142(11):2198-2206. PubMed ID: 29143328
[TBL] [Abstract][Full Text] [Related]
6. [Anti-EGFR monoclonal antibodies in recurrent and/or metastatic head and neck squamous cell carcinoma: a meta-analysis].
Song Q; Li X; Li B; Di B; Xiao S
Zhonghua Yi Xue Za Zhi; 2015 Jun; 95(22):1779-83. PubMed ID: 26704167
[TBL] [Abstract][Full Text] [Related]
7. Anti-EGFR monoclonal antibody plus chemotherapy for treating advanced non-small cell lung cancer: A meta-analysis.
Luo W; Li Y; Ye F; Li Q; Zhang G; Li J; Li X
Medicine (Baltimore); 2021 Nov; 100(47):e27954. PubMed ID: 34964780
[TBL] [Abstract][Full Text] [Related]
8. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
Cohen RB
Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
[TBL] [Abstract][Full Text] [Related]
9. p16(INK4a) status and survival benefit of EGFR inhibitors in head and neck squamous cell cancer: A systematic review and meta-analysis.
Su Y; Cui J; Xu D; Wang M; Xu T; Tian H; Han F
Crit Rev Oncol Hematol; 2018 Apr; 124():11-20. PubMed ID: 29548481
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials.
Liu L; Cao Y; Tan A; Liao C; Gao F
Cancer Chemother Pharmacol; 2010 Apr; 65(5):849-61. PubMed ID: 19680654
[TBL] [Abstract][Full Text] [Related]
11. The primary site of head and neck squamous cell carcinoma predicts survival benefits of EGFR inhibitors: A systematic review and meta-analysis.
Nie D; Wang X; Sun M; Feng Z; Pei F; Liu W; Wang Z; Han F
Radiother Oncol; 2021 May; 158():13-20. PubMed ID: 33587969
[TBL] [Abstract][Full Text] [Related]
12. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
Sun L; Ma JT; Zhang SL; Zou HW; Han CB
Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
[TBL] [Abstract][Full Text] [Related]
14. An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck.
Saloura V; Cohen EE; Licitra L; Billan S; Dinis J; Lisby S; Gauler TC
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1227-39. PubMed ID: 24714973
[TBL] [Abstract][Full Text] [Related]
15. Anti-EGFR-targeting agents in recurrent or metastatic head and neck carcinoma: a meta-analysis.
Petrelli F; Barni S
Head Neck; 2012 Nov; 34(11):1657-64. PubMed ID: 21953841
[TBL] [Abstract][Full Text] [Related]
16. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
Wirth LJ; Dakhil S; Kornek G; Axelrod R; Adkins D; Pant S; O'Brien P; Debruyne PR; Oliner KS; Dong J; Murugappan S
Oral Oncol; 2016 Oct; 61():31-40. PubMed ID: 27688102
[TBL] [Abstract][Full Text] [Related]
17. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
Burtness B
Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
[TBL] [Abstract][Full Text] [Related]
18. Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Crit Rev Oncol Hematol; 2015 Feb; 93(2):127-35. PubMed ID: 25139841
[TBL] [Abstract][Full Text] [Related]
19. Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer.
Siano M; Molinari F; Martin V; Mach N; Früh M; Freguia S; Corradino I; Ghielmini M; Frattini M; Espeli V
Oncologist; 2017 Jul; 22(7):782-e70. PubMed ID: 28592616
[TBL] [Abstract][Full Text] [Related]
20. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
